semaglutide biosimilar China advances biosimilars, Jiuyuan seeks NMPA nod DrReddy's launches oral #semaglutide biosimilar

doi: 10.17925/EE.2022.18.1.10

Medical Writing Assistance The authors thank Manthan Mehta, Kumardeep Paul, Syed Rahman, Mansij Biswas, Arpit Jain, Jignesh Ved, from Boehringer Ingelheim (India) medical affairs for providing writing assistance for this manuscript in accordance with Good Publication Practice (GPP3) guidelines ( Authorship All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published

It is also a primary tool for repairing the gut lining and reducing systemic inflammation

THNR launched in May 2024 and has $2.9 million in AUM

It is used with coenzyme Q10 for supporting the heart